Diabetes drug Avandia increases heart attack risk: report

0 Comments | AFP, September, 2007

WASHINGTON (AFP) — An analysis of four clinical trials involving more than 14,000 patients found that diabetes medication Avandia (rosiglitazone) taken over a lengthy period of time increases the risk of heart attack by 42 percent, a report released Tuesday said.

It marks one of the first studies to look at how use for one year or longer of Avandia, in patients with type 2 diabetes, affects risk of heart attack, heart failure and mortality, according to authors of the study in the September 12 issue of the Journal of The American Medical Association (JAMA).

The Food and Drug Administration recently required a label to be put on Avandia, made by British drugmaker GlaxoSmithKline, and similar treatments, warning of increased risk of heart failure.

An analysis...

Premium Content Partnership | MyWire provides an in-depth online archive library of reference works. MyWire
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)